Español
Català
English
- INVIVO PARTNERS

Invivo Partners is preparing to launch a €100M Invivo Ventures III Fund to invest in Leading-Edge Life Sciences

- INVIVO PARTNERS

ARTHEx Biotech Receives IND Clearance from FDA to Initiate the Phase I-IIa ArthemiR™ Trial of ATX-01 for Myotonic Dystrophy Type 1 (DM1)

- INVIVO PARTNERS

OneChain Immunotherapeutics announces appointment of Dr Stefanos Theoharis as new CEO

- INVIVO PARTNERS

JOB OPPORTUNITY / INTERNSHIP PROGRAM: Are you willing to start a career in the #VentureCapital space? Our internship program is now open. Apply now!

- INVIVO PARTNERS

Invivo Ventures Invests in EsoBiotec to Revolutionize Cancer Cell Therapy with Cutting-Edge In Vivo Engineering Platform

- EXPANSIÓN CATALUNYA

Invivo invests two million in Belgium's EsoBiotec

- CAPITAL RIESGO

Invivo Ventures Invests in EsoBiotec to Revolutionize Cancer Cell Therapy with Cutting-Edge In Vivo Engineering Platform

-

JOB OPPORTUNITY: We are currently seeking a Senior Investment Professional with a strong scientific background and professional experience in Venture Capital to join our team. Apply now!

- INVIVO PARTNERS

PORTFOLIO NEWS: We are excited to announce that our portfolio company, OneChain, has raised €6.7M in a pre-Series A funding round. The round involved the participation of venture capital firm Invivo Partners, the Center for Technological Development and Innovation, venture capital firms Nara Capital and Clave Capital, and the Josep Carreras Foundation against leukemia.

- INVIVO PARTNERS

PORTFOLIO NEWS: Congratulations to ARTHEx Biotech for successfully closing a €42M Series B financing round to advance their novel treatment for Myotonic Dystrophy Type 1 (DM1). We are proud to have been their first investor, discovering the company in 2019.

-

JOB OPPORTUNITY: We’re seeking candidates with a strong scientific background and professional experience to join our team as Investment Analyst. Apply now!

- INVIVO PARTNERS

JOB OPPORTUNITY / INTERNSHIP PROGRAM: We're seeking candidates to join us. Apply now!

- INVIVO PARTNERS

We are excited to announce that Claudio Santos has joined us as Entrepreneur in Residence to support our company creation activity in the technology transfer space

- INVIVO PARTNERS

JOB OPPORTUNITY: Our portfolio company Telomere Therapeutics is seeking candidates for a Project Manager position.

- EXPANSIÓN CATALUNYA

Genfit To Acquire Versantis

- INVIVO CAPITAL

We’re pleased to announce our second exit in less than a year: Genfit has announced it will acquire Versantis.

- EXPANSIÓN

Investing In Leading-Edge. Article published today in Expansión with the participation of Luis Pareras.

- INVIVO CAPITAL

JOB OPPORTUNITY: We’re seeking candidates with a strong scientific background to join our #internship opportunity. If you’re interested in learning how a #VC firm works, please apply!

- INVIVO CAPITAL

JOB OPPORTUNITY: We are looking for Controller candidates. If you are interested, please apply!

- INVIVO CAPITAL

Integra Therapeutics completes the €6-million seed round with the addition of Columbus Venture Partners

- INVIVO CAPITAL

Invivo Capital invests together with Kurma Partners, V-Bio Ventures and Omnes Capital in Corteria Pharmaceuticals, a French biotechnology company developing novel therapies for heart failure subpopulations with a high unmet clinical need.

- EXPANSIÓN CATALUÑA

Integra Tx raises 4.5 million from Advent, Invivo and Takeda

- INVIVO CAPITAL

Integra Tx secures €4.5-million in funding from Invivo Capital, Advent France Biotechnology and Takeda Ventures

- INVIVO CAPITAL

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

- AJUNTAMENT DE BARCELONA

L’Ajuntament de Barcelona ha seleccionat Invivo Ventures FCR junt amb altres 5 fons de capital risc privats per participar en la iniciativa Barcelona Accelera

- Expansión (Ed. Cataluña)

Peptomyc capta 11,4 millones para iniciar un ensayo clínico en cáncer

- Minoryx Therapeutics

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia

- INVIVO CAPITAL

Invivo boosts a gene therapy startup, Telomere Therapeutics, with 1.5 million

- INVIVO CAPITAL

Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology

- WEB CAPITAL RIESGO

Invivo Ventures, CDTI-Innvierte y la Fundación Josep Carreras cierran una ronda de €3,05 millones en OneChain Immunotherapeutics.

- CAPITAL RIESGO

Invivo Ventures, CDTI-Innvierte y la Fundación Josep Carreras cierran una ronda de financiación de 3.050.000€ en OneChain Immunotherapeutics

- INVIVO CAPITAL

The Josep Carreras Institute creates a spin-off to develop therapies for leukaemia based on CAR–T

- INVIVO CAPITAL

Telum Therapeutics raises € 4.1 million in its first round of financing to advance the development of new synthetic biology-based therapies for the treatment of infectious diseases caused by multi-resistant bacteria.

- PLANTA DOCE

Telum Therapeutics cierra una ronda de 4,1 millones liderada por Invivo Ventures

- WEBCAPITALRIESGO

Invivo Ventures invierte €1,5 millones en Gyala Therapeutics

- CAPITAL RIESGO

Invivo Ventures invierte 1,5 millones en Gyala Therapeutics

- Planta Doce

Gyala Therapeutics capta 1,5 millones de euros de Invivo Ventures

- INVIVO CAPITAL

A new cancer immune therapy spin-off of Hospital Clínic-IDIBAPS (Barcelona) secures a 1.5 million-euro investment from Invivo Ventures

- Expansión

Invivo Ventures invierte dos millones en la biotecnológica Pulmobiotics

- La Vanguardia

Pulmobiotics consigue dos millones para su inhalador

- Invivo Capital

Barcelona-based synthetic biology company secures two-million-euro investment

- Planta Doce

Invivo Ventures impulsa Pulmobiotics con una ‘inyección’ inicial de dos millones de euros

- PlantaDoce

Invivo Ventures lidera una ronda de financiación de 1,5 millones en Arthex Biotech

- Expansión Cataluña

El fondo Invivo Ventures debuta con una ronda de 1,5 millones en Arthex Biotech

- La Vanguardia

Invivo Ventures lidera una ronda de 1,5 millones

- INVIVO CAPITAL

Invivo Ventures FCR, a new venture capital fund in the biomedical sector

- Expansión Cataluña

Invivo invertirá 40 millones en el sector biomédico

- Expansión Cataluña

Invivo se estrena con un fondo biomédico de 40 millones

- PlantaDoce

Invivo Capital abre su fondo biomédico con 40 millones de euros

TOP